Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Talzenna talazoparib Breast cancer CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Tarceva Erlotinib Cancer, Lung , non-small cell List with clinical criteria and/or conditions Complete
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Targin Oxycodone HCI / naloxone HCI Pain, moderate to severe and relief of opioid-induced constipation Do not list Complete
Tavalisse fostamatinib Chronic immune thrombocytopenia Do not reimburse Complete
Tavneos avacopan Antineutrophil cytoplasmic antibody-associated vasculitis Do not reimburse Complete
TBC risperidone Schizophrenia, adults Suspended
TBC ruxolitinib atopic dermatitis Suspended
TBC lebrikizumab atopic dermatitis Active
TBC avapritinib Advanced Systemic Mastocytosis Pending